Pre-Clinical Efficacy and Safety Evaluation of Human Amniotic Fluid-Derived Stem Cell Injection in a Mouse Model of Urinary Incontinence
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Stem cell-based therapies represent new promises for the treatment of urinary incontinence. This study was performed to assess optimized cell passage number, cell dose, therapeutic efficacy, feasibility, toxicity, and cell trafficking for the first step of the pre-clinical evaluation of human amniotic fluid stem cell (hAFSC)therapy in a urinary incontinence animal model. Materials and Methods: The proper cell passage number was analyzed with hAFSCs at passages 4, 6, and 8 at week 2. The cell dose optimization included 1×104, 1×105, and 1×106 cells at week 2. The in vivo cell toxicity was performed with 0.25×106, 0.5×106, and 1×106 cells at weeks 2 and 4. Cell tracking was performed with 1×106 cells at weeks 2 and 4. Results: The selected optimal cell passage number was smaller than 6, and the optimal cell dose was 1×106 for the mouse model. In our pre-clinical study, hAFSC-injected animals showed normal values for several parameters. Moreover, the injected cells were found to be non-toxic and non-tumorigenic. Furthermore, the injected hAFSCs were rarely identified by in vivo cell trafficking in the target organs at week 2. Conclusion: This study demonstrates for the first time the pre-clinical efficacy and safety of hAFSC injection in the urinary incontinence animal model and provides a basis for future clinical applications.
Abstract
Purpose: Stem cell-based therapies represent new promises for the treatment of urinary incontinence. This study was performed to assess optimized cell passage number, cell dose, therapeutic efficacy, feasibility, toxicity, and cell trafficking for the first step of the pre-clinical evaluation of human amniotic fluid stem cell (hAFSC)therapy in a urinary incontinence animal model. Materials and Methods: The proper cell passage number was analyzed with hAFSCs at passages 4, 6, and 8 at week 2. The cell dose optimization included 1×104, 1×105, and 1×106 cells at week 2. The in vivo cell toxicity was performed with 0.25×106, 0.5×106, and 1×106 cells at weeks 2 and 4. Cell tracking was performed with 1×106 cells at weeks 2 and 4. Results: The selected optimal cell passage number was smaller than 6, and the optimal cell dose was 1×106 for the mouse model. In our pre-clinical study, hAFSC-injected animals showed normal values for several parameters. Moreover, the injected cells were found to be non-toxic and non-tumorigenic. Furthermore, the injected hAFSCs were rarely identified by in vivo cell trafficking in the target organs at week 2. Conclusion: This study demonstrates for the first time the pre-clinical efficacy and safety of hAFSC injection in the urinary incontinence animal model and provides a basis for future clinical applications.
참고문헌 (20)
- Sassani P, "Stress urinary incontinence in women", Curr Urol Rep, 10, pp.333~337 (2009)
- Kim SO, "Bone-marrow-derived mesenchymal stem cell transplantation enhances closing pressure and leak point pressure in a female urinary incontinence rat model", Urol Int, 86, pp.110~116 (2011)
- Kim BS, "Human amniotic fluid stem cell injection therapy for urethral sphincter regeneration in an animal model", BMC Med, 10, pp.94~ (2012)
- 전소영, "Human Amniotic Fluid Stem Cell-derived Muscle Progenitor Cell Therapy for Stress Urinary Incontinence", Journal of Korean Medical Science, 27(11), pp.1300~1307 (2012), 대한의학회
- Kim H, "Dose-dependent efficacy of ALS-human mesenchymal stem cells transplantation into cisterna magna in SOD1-G93A ALS mice", Neurosci Lett, 468, pp.190~194 (2010)
- Morita E, "A novel cell transplantation protocol and its application to an ALS mouse model", Exp Neurol, 213, pp.431~438 (2008)
- Banfi A, "Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: implications for their use in cell therapy", Exp Hematol, 28, pp.707~715 (2000)
- Bruder SP, "Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation", J Cell Biochem, 64, pp.278~294 (1997)
- Uccelli A, "Mesenchymal stem cells in health and disease", Nat Rev Immunol, 8, pp.726~736 (2008)
- Rocha V, "Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European survey", J Clin Oncol, 20, pp.4324~4330 (2002)
- Hohaus S, "Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer", Semin Oncol, 25(2 Suppl 4), pp.7~11 (1998)
- Plitnick LM, "Nonclinical development of novel biologics, biosimilars, vaccines and specialty biologics", pp.388~390 (2013), Academic Press
- De Coppi P, "Isolation of amniotic stem cell lines with potential for therapy", Nat Biotechnol, 25, pp.100~106 (2007)
- Choi MR, "Selection of optimal passage of bone marrow-derived mesenchymal stem cells for stem cell therapy in patients with amyotrophic lateral sclerosis", Neurosci Lett, 472, pp.94~98 (2010)
- Digirolamo CM, "Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate", Br J Haematol, 107, pp.275~281 (1999)
- Haynesworth SE, "Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha", J Cell Physiol, 166, pp.585~592 (1996)
- Liu CH, "Cytokine interactions in mesenchymal stem cells from cord blood", Cytokine, 32, pp.270~279 (2005)
- Faustman DL, "Stem cells in the spleen: therapeutic potential for Sjogren’s syndrome, type I diabetes, and other disorders", Int J Biochem Cell Biol, 42, pp.1576~1579 (2010)
- Nauta AJ, "Immunomodulatory properties of mesenchymal stromal cells", Blood, 110, pp.3499~3506 (2007)
- Itoi M, "Mesenchymal cells are required for functional development of thymic epithelial cells", Int Immunol, 19, pp.953~964 (2007)